丰倍生物
(603334)
| 流通市值：10.21亿 | | | 总市值：46.03亿 |
| 流通股本：3181.67万 | | | 总股本：1.44亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,346,738,610.6 | 1,108,730,173.16 | 3,170,795,556.18 | 2,251,405,158.14 |
| 营业收入 | 2,346,738,610.6 | 1,108,730,173.16 | 3,170,795,556.18 | 2,251,405,158.14 |
| 二、营业总成本 | 2,270,316,203.73 | 1,076,029,075.77 | 3,057,754,762.06 | 2,150,718,766.31 |
| 营业成本 | 2,194,328,754.32 | 1,041,954,277.29 | 2,911,878,853.16 | 2,048,471,846.61 |
| 税金及附加 | 6,227,308.84 | 2,621,372.69 | 11,518,643.14 | 8,321,868.46 |
| 销售费用 | 10,390,941.65 | 4,070,055.73 | 20,780,735.85 | 14,099,991.68 |
| 管理费用 | 19,609,382.94 | 9,432,960.11 | 37,464,546.36 | 24,460,138.66 |
| 研发费用 | 32,395,485.59 | 14,253,129.99 | 68,180,579.01 | 51,128,748.5 |
| 财务费用 | 7,364,330.39 | 3,697,279.96 | 7,931,404.54 | 4,236,172.4 |
| 其中:利息费用 | 1,114,077.42 | 637,208.5 | 7,694,244.89 | 4,831,755.99 |
| 其中:利息收入 | 586,225.44 | 393,437.45 | 1,072,643.18 | 524,394.27 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -92,927.39 | -184,018.53 | 423,386.97 | 191,871.01 |
| 加:投资收益 | 909,745.03 | 445,708.23 | 124,881.53 | -444,144.69 |
| 资产处置收益 | - | - | 32,843.57 | 729.51 |
| 资产减值损失(新) | -1,751,923.6 | 161,966.54 | -2,558,367.91 | -800,186.49 |
| 信用减值损失(新) | -12,196,318.83 | 1,323,156.85 | -3,482,791.88 | -4,058,782.25 |
| 其他收益 | 30,904,747.96 | 11,569,881.62 | 46,372,650.16 | 32,209,434.29 |
| 四、营业利润 | 94,195,730.04 | 46,017,792.1 | 153,953,396.56 | 127,785,313.21 |
| 加:营业外收入 | 18,998.74 | 5,863.56 | 35,993.42 | 20,298.54 |
| 减:营业外支出 | 1,317,084.31 | 181,957.64 | 493,909.66 | 111,781.7 |
| 五、利润总额 | 92,897,644.47 | 45,841,698.02 | 153,495,480.32 | 127,693,830.05 |
| 减:所得税费用 | 11,432,931.64 | 4,930,189.03 | 12,970,238.96 | 10,395,003.57 |
| 六、净利润 | 81,464,712.83 | 40,911,508.99 | 140,525,241.36 | 117,298,826.48 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 81,464,712.83 | 40,911,508.99 | 140,525,241.36 | 117,298,826.48 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 81,425,143.77 | 40,879,056.33 | 140,554,623.92 | 117,298,826.48 |
| 少数股东损益 | 39,569.06 | 32,452.66 | -29,382.56 | - |
| 扣除非经常损益后的净利润 | 81,191,438.23 | 34,220,007.78 | 136,677,787.16 | 116,678,526.48 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.57 | 0.28 | 1.24 | 1.09 |
| (二)稀释每股收益 | 0.57 | 0.28 | 1.24 | 1.09 |
| 九、综合收益总额 | 81,464,712.83 | 40,911,508.99 | 140,525,241.36 | 117,298,826.48 |
| 归属于母公司股东的综合收益总额 | 81,425,143.77 | 40,879,056.33 | 140,554,623.92 | 117,298,826.48 |
| 归属于少数股东的综合收益总额 | 39,569.06 | 32,452.66 | -29,382.56 | - |
| 公告日期 | 2026-08-24 | 2026-04-29 | 2026-04-10 | 2025-11-04 |
| 审计意见(境内) | | | 标准无保留意见 | |